[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Masaryk Memorial Cancer Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,77,105,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644605","comprehensive-perioperative-program-based-on-prehabilitation-nutritional-intervention-and-psychological-support-for-patients-with-locally-advanced-operable-oesophagogastric-cancer-100644605",false,"NCT07671625","Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally Advanced Operable Oesophagogastric Cancer","A Comprehensive Preoperative and Postoperative Program Consisting Of Active Physical Therapy, A Comprehensive Nutritional Plan, And Psychological Support For Patients With Locally Advanced, Resectable Cancer Of The Esophagus, Gastroesophageal Junction, and Stomach","OESOFIT","Inclusion Criteria:\n\n* Consent to participate in the study\n* Age ≥ 18 years\n* Patients with locally advanced esophageal or gastric cancer indicated for comprehensive perioperative treatment\n* Resectable disease\n* ECOG performance status 0-2\n* Ability to participate in a fitness program\n* Willingness to follow a nutritional plan and recommendations\n\nExclusion Criteria:\n\n* Disseminated disease","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Perioperative chemotherapy (CHT) or CHT\u002FRT combined with surgery is the standard therapeutic approach for the treatment of locally advanced cancer of the esophagus, gastroesophageal junction (GEJ), and stomach. Comprehensive cancer treatment is associated with high perioperative morbidity and mortality. Serious postoperative complications occur in up to 20-80% of patients undergoing esophagectomy. The impact of nutritional status and overall physical condition on surgical outcomes and overall treatment has been demonstrated many times. The concept of pre-rehabilitation\u002Fpre-optimization, which involves establishing an individualized nutritional plan, monitoring and managing physical activity, and providing comprehensive supportive oncological and psychological care as early as during neoadjuvant CHT or CHT\u002FRT, is a prerequisite for improving perioperative and 30-day postoperative morbidity and mortality.",[27,28,29],"Locally Advanced Esophageal Cancer","Gastroesophageal Junction Cancer","Gastric Cancer",[31,32,33,34,35,36],"autonomic nervous system","physiotherapy","gastric cancer","nutritional intervention","psychologic support","esophageal cancer","RECRUITING","2026-06-25",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":41},"2023-05-02",{"date":45,"type":21},"2026-12-31",{"name":47,"class":48},"Masaryk Memorial Cancer Institute","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":76,"locationsCount":49},"100641907","determining-minimal-residual-disease-using-ctdna-deep-sequencing-100641907","NCT07660627","Determining Minimal Residual Disease Using ctDNA Deep Sequencing","Determination of Minimal Residual Disease by Deep ctDNA Sequencing.","CIT-SEQ","Inclusion Criteria:\n\n* Consent to participate in the study\n* Patients with esophageal, gastric, or pancreatic cancer, stage 0-2\n* Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy\n* Patients with metastatic disease treated with first- to third-line palliative systemic therapy\n\nExclusion Criteria:\n\n* not specified",{"count":59,"type":21},34,[24],"Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse\u002Fprogression of disease.",[63,29,64],"Esophageal Adenocarcinoma","Pancreatic Cancer",[66,67,68,69],"Minimal residual disease","NGS sequencing","gastrointestinal tumors","Preoperative neoadjuvant chemotherapy","2026-06-19",{"date":72,"type":41},"2026-06-24",{"date":74,"type":41},"2022-08-22",{"date":45,"type":21},{"name":47,"class":48},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":104,"locationsCount":49},"100612469","cancer-survivors-program-100612469","NCT07253987","Cancer Survivors Program","Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer","SURV-QoL","Inclusion Criteria:\n\n* The patient understands the information provided and agrees to participate in the study.\n* Age 18 years or older.\n* Histologically confirmed invasive breast cancer or invasive prostate cancer.\n* Completion of the acute phase of curative oncological therapy:\n\n  * for breast cancer: curative surgery performed + completed neoadjuvant\u002Fadjuvant chemotherapy and completed adjuvant radiotherapy, if indicated\n  * for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy\n* The patient is available for follow-up within 12 months of enrollment in the study.\n\nExclusion Criteria:\n\n* Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4\u002F6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)\n* Neoadjuvant\u002Fadjuvant therapy did not include chemotherapy (breast cancer).\n* Recurrence of cancer\n* Metastatic disease\n* History of other primary malignancy (except for non-melanoma skin cancer)",{"count":86,"type":21},200,[24],"The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.",[90,91],"Prostate Cancer Patients","Breast Cancer Patients",[93,94,95,96,97],"cancer survivors","breast cancer","prostate cancer","neo-\u002Fadjuvant chemotherapy","quality of life","2026-06-10",{"date":100,"type":41},"2026-06-11",{"date":102,"type":41},"2025-05-05",{"date":45,"type":21},{"name":47,"class":48},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":49},"100541482","pancreatic-cancer-screening-in-a-population-at-high-risk-100541482","NCT06330441","Pancreatic Cancer Screening in a Population at High Risk","ScrePan","Inclusion Criteria:\n\n* willing to participate in the study\n* age 18+\n* arms specific criteria:\n\nA:\n\n* chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis\n* age 50+\n\nB1:\n\n* confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member\n* familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member\n* confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack\n\nB2:\n\n* confirmed diagnosis of hereditary syndrome (Lynch syndrome \u002FmutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM\u002F, HBOC \u002FmutBRCA1, mutBRCA2, mutPALB2, mutATM\u002F, familial adenomatous polyposis \u002FmutAPC\u002F, Li-Fraumeni syndrome \u002FmutTP53\u002F)\n* at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative)\n* age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first\n\nC:\n\n* positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context\n* age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members\n\nExclusion Criteria:\n\n* Inability to undergo radical curative surgery for a pancreatic tumor.\n* Inability to undergo scheduled imaging examinations.\n* Incurable malignant cancer.",{"count":113,"type":21},700,[24],"Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: \"Pancreatic Cancer Screening in High-Risk Persons\".",[117,118,119],"Pancreatic Ductal Adenocarcinoma","Hereditary Diseases","Pancreatitis, Chronic",[121,122,123],"pancreatic ductal adenocarcinoma","screening programme","high-risk population","2026-04-16",{"date":126,"type":41},"2026-04-21",{"date":128,"type":41},"2022-01-07",{"date":130,"type":21},"2028-01-06",{"name":47,"class":48},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":49},"100343432","acupuncture-as-the-therapeutic-modalities-of-acute-toxicity-in-the-radiotherapy-of-head-and-neck-tumors-100343432","NCT03751566","Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors","Inclusion Criteria:\n\n* Curative and adjuvant radiotherapy for head and neck tumors;\n* PS 1-2;\n* Patient collaboration in evaluation of the toxicity diary.\n\nExclusion Criteria:\n\n* Palliative radiotherapy in the head and neck tumor;\n* PS 3;\n* Non-compliance of the patient.",{"count":20,"type":21},[24],"The aim of the study is to evaluate the benefit of the acupuncture as healing modalities in the therapy of acute toxicity of radiotherapy.",[142],"Malignant Tumor of Soft Tissue of Head, Face and Neck","2025-09-23",{"date":145,"type":41},"2025-09-25",{"date":147,"type":41},"2021-10-05",{"date":149,"type":21},"2026-10-04",{"name":47,"class":48},""]